Equillium announces positive interim data with itolizumab in acute gvhd study

Equillium - announces positive interim data with itolizumab in acute gvhd study; covid-19 pre-ind meeting request, briefing package submitted to fda.equillium inc - across first two dose cohorts itolizumab has been generally well tolerated to date.equillium inc - five of seven patients achieved a complete response (cr) by day 29.
EQ Ratings Summary
EQ Quant Ranking